Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

Search
Advanced Search
OPEN ACCESS
mobile search button mobile menu button

Search

Page Path
HOME > Search
1 "So Hyun Nam"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Article
Gynecologic cancer
Safety and Tolerability of Weekly Genexol-PM, a Cremophor-Free Polymeric Micelle Formulation of Paclitaxel, with Carboplatin in Gynecologic Cancer: A Phase I Study
So Hyun Nam, Shin-Wha Lee, Young-Jae Lee, Yong Man Kim
Cancer Res Treat. 2023;55(4):1346-1354.   Published online May 15, 2023
DOI: https://doi.org/10.4143/crt.2022.1436
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This phase I study was conducted to determine the maximum tolerated dose and the recommended phase II dose of weekly administered Genexol-PM combined with carboplatin in patients with gynecologic cancer.
Materials and Methods
This open-label, phase I, dose-escalation study of weekly Genexol-PM included 18 patients with gynecologic cancer, who were equally divided into three cohorts of dose levels. Cohort 1 received 100 mg/m2 Genexol-PM and 5 area under the curve (AUC) carboplatin, cohort 2 received 120 mg/m2 Genexol-PM and 5 AUC carboplatin, and cohort 3 received 120 mg/m2 Genexol-PM and 6 AUC carboplatin. The safety and efficacy of each dose were analyzed for each cohort.
Results
Of the 18 patients, 11 patients were newly diagnosed and seven patients were recurrent cases. No dose-limiting toxicity was observed. The maximum tolerated dose was not defined, but a dose up to 120 mg/m2 of Genexol-PM in combination with AUC 5-6 of carboplatin could be recommended for a phase II study. In this intention-to-treat population, five patients dropped out of the study (carboplatin-related hypersensitivity, n=1; refusal of consent, n=4). Most patients (88.9%) with adverse events recovered without sequelae, and no treatment-related death occurred. The overall response rate of weekly Genexol-PM in combination with carboplatin was 72.2%.
Conclusion
Weekly administered Genexol-PM with carboplatin demonstrated an acceptable safety profile in gynecologic cancer pati-ents. The recommended phase II dose of weekly Genexol-PM is up to 120 mg/m2 when combined with carboplatin.

Citations

Citations to this article as recorded by  
  • Long-acting lipid-based nanomedicines: rethinking from structure-based rational design to in vivo fate evaluation
    Yixuan Tang, Shan Lu, Wanjun Liang, Yujing He, Jifu Hao, Wei Xu, Yuansong Sun, Changyou Zhan
    Journal of Controlled Release.2026; 389: 114465.     CrossRef
  • Nanotechnology-Driven Cancer Therapies for Precision Oncology: Advances and Clinical Outlook
    Vrinda Gupta, Dinesh Kumar, Sonia Gupta, Rajni Tanwar, Nicky Jaiswal, Md Moidul Islam, Shivani Singh, Niraj Choudhary, S Gowri, Thomas Webster, Md Faiyazuddin
    International Journal of Nanomedicine.2026; Volume 21: 1.     CrossRef
  • The Current Landscape of Nanopaclitaxel Formulations and the Benefits of Polymeric Micellar Paclitaxel in Solid Tumors
    Vaibhav Choudhary, Nirmal Raut, Gajanan Panchal, Maneesha Khalse, Kamlesh Patel
    Indian Journal of Medical and Paediatric Oncology.2026;[Epub]     CrossRef
  • Layers of Hope: How Graphene and Nanostructures Hold Promise for Cancer Therapy
    Beatriz Fumelli Monti Ribeiro, Gláucia Maria Machado-Santelli
    International Journal of Molecular Sciences.2026; 27(5): 2336.     CrossRef
  • Multicore, SDS-Based Polyelectrolyte Nanocapsules as Novel Nanocarriers for Paclitaxel to Reduce Cardiotoxicity by Protecting the Mitochondria
    Marzena Szwed, Anastazja Poczta-Krawczyk, Katarzyna D. Kania, Kacper Wiktorowski, Kamila Podsiadło, Agnieszka Marczak, Krzysztof Szczepanowicz
    International Journal of Molecular Sciences.2025; 26(3): 901.     CrossRef
  • Potent therapeutic efficacy of intranasally deliverable paclitaxel modified with pH-sensitive and PEGylated polymeric micelle against glioblastoma
    Young-Beom Kim, Soo-Hwan Lee, Dayananda Kasala, Yuebin Zhao, Ao Jiao, JinWoo Hong, Jin Su Kim, A-Rum Yoon, Chae-Ok Yun
    Journal of Controlled Release.2025; 382: 113711.     CrossRef
  • Nanomaterials-driven in situ vaccination: a novel frontier in tumor immunotherapy
    Naimeng Liu, Xiangyu Wang, Zhongzhao Wang, Yonemori Kan, Yi Fang, Jidong Gao, Xiangyi Kong, Jing Wang
    Journal of Hematology & Oncology.2025;[Epub]     CrossRef
  • Advances in the use of nanomicelles to enhance the efficacy of antitumour substances (review)
    E. V. Sanarova, L. L. Nikolaeva, S. D. Shceglov, Zh. M. Kozlova, O. L. Orlova, N. A. Oborotova, A. V. Lantsova
    Drug development & registration.2025;[Epub]     CrossRef
  • Current insights into polymeric micelles for nasal drug delivery
    Bence Sipos, Fatima Rajab, Gábor Katona, Ildikó Csóka
    Expert Opinion on Drug Delivery.2025; 22(8): 1137.     CrossRef
  • Rational design of paclitaxel prodrugs for facile preparation of in-situ therapeutic system in antitumor applications
    Lanqing Wang, Zhaofan Yang, Guanyu Jin, Bingzheng Yu, Wei Zhang, Xuesi Chen, Haochen Yao, Cuiping Yao, Shixian Lv
    Chemical Engineering Journal.2025; 518: 164599.     CrossRef
  • Nanoformulation-based drug delivery systems for the treatment of gastric cancer: recent developments and future prospects
    Jiale Zou, Siwen Chen, Wenhui Liu, Yishu Wang, Diwei Zheng, Wenqiang Sun, Shiping Xu, Wei Wei, Shuang Wang
    Nanoscale Horizons.2025; 10(11): 2722.     CrossRef
  • Gemcitabine and Cisplatin Plus Polymeric Micellar Paclitaxel and Survival in Advanced Biliary Tract Cancer
    Hyehyun Jeong, Changhoon Yoo, Ilhwan Kim, Jung Hun Kang, Jae Ho Jeong, Kwonoh Park, Sang-Bo Oh, Inkeun Park, Sun Jin Sym, Jaekyung Cheon, Hyewon Ryu, Jun Eul Hwang, Ji Sung Lee, Baek-Yeol Ryoo, Kyu-pyo Kim
    JAMA Network Open.2025; 8(10): e2534560.     CrossRef
  • A Comprehensive Review on Advancements in Nanocarriers-Based Peptide Delivery for Cancer Therapeutics
    Sayad Ahad Ali, Shadab Ali, Sonali Rastogi, Brijesh Shivhare, Mohammad Muztaba, Shamim Shamim
    Micro and Nanosystems.2025; 17(4): 283.     CrossRef
  • Recent Advances in the Applications of Biomaterials in Ovarian Cancer
    A Mahfuz, Amol Janorkar, Rodney Rocconi, Yuanyuan Duan
    Biomimetics.2025; 10(11): 768.     CrossRef
  • Redox-responsive polymer micelles co-encapsulating immune checkpoint inhibitors and chemotherapeutic agents for glioblastoma therapy
    Zhiqi Zhang, Xiaoxuan Xu, Jiawei Du, Xin Chen, Yonger Xue, Jianqiong Zhang, Xue Yang, Xiaoyuan Chen, Jinbing Xie, Shenghong Ju
    Nature Communications.2024;[Epub]     CrossRef
  • Therapeutic impacts of GNE‑477‑loaded H2O2 stimulus‑responsive dodecanoic acid‑phenylborate ester‑dextran polymeric micelles on osteosarcoma
    Songmu Pan, Zhuan Zou, Xiaofeng Zhou, Jiyong Wei, Huijiang Liu, Zhongyi Su, Gui Liao, Guangyu Huang, Zonggui Huang, Yi Xu, Minan Lu, Ronghe Gu
    International Journal of Molecular Medicine.2024;[Epub]     CrossRef
  • Functionalized Polymeric Micelles for Targeted Cancer Therapy: Steps from Conceptualization to Clinical Trials
    Ana Serras, Célia Faustino, Lídia Pinheiro
    Pharmaceutics.2024; 16(8): 1047.     CrossRef
  • Simplified Gambogic Acid Prodrug Nanoparticles to Improve Efficiency and Reduce Toxicity for Clinical Translation Potential
    Ruyi Wang, Yuxiao Xiao, Zhongtao Zhang, Xiaoxian Huang, Wanfang Zhu, Xiao Ma, Feng Feng, Wenyuan Liu, Lingfei Han, Wei Qu
    Advanced Healthcare Materials.2024;[Epub]     CrossRef
  • 6,297 View
  • 201 Download
  • 17 Web of Science
  • 18 Crossref
Close layer
Cancer Res Treat : Cancer Research and Treatment
© Korean Cancer Association.
Close layer
TOP